

1 **Supplemental Table 1. Patient characteristics at sevelamer initiation: Comparison of**
2 **matched vs. unmatched patients**

Characteristic	Sevelamer-treated patients	
	N=2,501 matched patients	N=105 unmatched patients
Demographics		
Age, yr	61 ± 14	54 ± 19
Male, %	58	73
Time on dialysis, mo	25 (6-65)	24 (6-43)
Body mass index, kg/m ²	26.1 ± 6.3	26.7 ± 6.1
Single-pool Kt/V	1.43 ± 0.32	1.37 ± 0.34
Comorbidities, %		
Coronary heart disease	44	31
Cancer	12	13
Other cardiovascular disease	31	28
Cerebrovascular disease	14	8
Congest heart failure	34	28
Diabetes	45	21
GI bleeding	4	4
Hypertension	85	89
Lung disease	12	13
Neurologic disease	9	8
Psychiatric disorder	13	11
Peripheral vascular disease	24	14
Recurrent cellulitis/gangrene	8	8
Laboratory tests		
Albumin, g/dl	3.8 ± 0.4	4.0 ± 0.7
Hemoglobin, g/dl	11.3 ± 1.4	11.9 ± 1.6
BUN (pre-dialysis), mg/dl	63.4 ± 18.5	67.6 ± 19.4
Creatinine, mg/dl	9.3 ± 2.9	10.8 ± 4.1
Calcium, mg/dl	9.2 ± 0.9	8.9 ± 0.9
Phosphorus, mg/dl	5.8 ± 1.7	5.7 ± 1.8
Intact PTH, pg/ml	217 (105-380)	210 (98-380)
Total cholesterol, mg/dl	159 ± 41	159 ± 42
Medication, %		
ESA	88	84
Active vitamin D derivatives ^a		
<i>Oral</i>	34	37
<i>IV</i>	24	22
Calcium carbonate	60	59
Lanthanum carbonate	6	11
Calcium channel blocker	40	31
ACEI/ARB	43	35

3 Data are shown as mean ± SD, median (interquartile range), or percentage. All values were
4 obtained at the time of prognostic score calculation for matching. BMI, body mass index; GI,

1 gastrointestinal; PTH, parathyroid hormone; ESA, erythropoiesis-stimulating agent; IV,
2 intravenous; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor
3 blocker.

4 ^aIncludes calcitriol, doxercalciferol, paricalcitol, maxacalcitol, alphacalcidol, and falecalcitriol.

5

6